Dr. Dapo (@DrDapo) header
Dr. Dapo (@DrDapo) profile picture

Dapo Iluyomade MD MBA FACC FAHA 🫀 Preventive Cardiologist @BaptistHealthSF || Assistant Prof of Medicine @FIUmedicine || #cvPrev 🇳🇬 Tweets mine.

Miami, FL
Joined October 2010
Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)Photo by Dr. Dapo (@DrDapo)
The term "VIP patient" further perpetuates existing disparities in healthcare. Let's work to treat all of our patients like the very important people that they are. 🤝🏾👩🏻‍⚕️⚕️⚖️🩺🏥 #HealthForAll #HealthEquity #HealthIsWealth
2
13
1
97
Coronary Artery Calcium Volume & Density Score in Cardiovascular Risk Assessment: Are We There Yet? | Circulation: CV Imaging ahajournals.org/doi/10.1161/… / led by @hsbhatia @AlexRazavi @ZeinaDardari @MichaelJBlaha & Michael Criqui @CiccaroneCenter @hopkinsheart #🥍🐦🫀⚽️🏏🏀🏈
12
35
2,121
Maybe this isn't surprising (but it was to me). Children between the ages of 6 and 12 with obesity – defined by a BMI in the ≥95th percentile – already have cardiometabolic dysfunction: high blood pressure, sugars, lipids, inflammation. That's mostly reversed with semaglutide – but, at the cost of slower growth (~25% slower with GLP1).
5
12
1
78
10,799
Great insights Must read 👇
Replying to @theproof
It’s complex, and these numbers alone cannot give a definitive answer about who is at higher risk. The answer will vary between individuals. Some densely calcified plaques have very low rupture risk, but calcium is not automatically synonymous with stability. Calcification often develops in and around the necrotic core, and its pattern, location and density matter. Conversely, noncalcified plaque does not necessarily contain a large necrotic core. CAC also reflects disease stage. In our JAMA Cardiology study of symptomatic patients with obstructive CAD, 58% of those aged <40 had CAC=0, compared with just 5% of those aged ≥70. The same degree of stenosis can therefore occur at very different stages of atherosclerosis. doi.org/10.1001/jamacardio.2… Further, in a previous JACC paper we also showed that obstructive CAD does not invariably imply high near-term event risk: patients with CAC=0 had low absolute event rates even when significant stenoses were present. doi.org/10.1016/j.jacc.2020.… At Aarhus, we have also investigated the cellular mechanisms underlying plaque development and calcification. For example, experimental work from our Aarhus/Madrid colleagues showed how cholesterol lowering depletes specific smooth muscle cell–derived populations, including fibromyocytes and chondromyocytes, during plaque regression. doi.org/10.1038/s44161-023-0… Early microscopic calcification, below the resolution of clinical CT, should also be distinguished from established, dense calcium deposits. With statin therapy, calcified plaque volume can increase, but calcium also becomes denser while lipid-rich plaque regresses. Taken together, equal plaque volume does not necessarily mean equal risk, and mild calcification can have different implications in different clinical settings. We cannot yet answer this comparison with certainty: individual risk depends on plaque type, composition, disease stage and the time horizon considered.
2
6
1,179
A healthy, balanced dietary pattern, rather than one focused on individual nutrients or foods, is key to maintaining heart health, according to a new ACC Scientific Statement in #JACC. Get the details with #CardiologyMag: bit.ly/4k88WDd @JACCJournals
3
33
5
106
8,304
🚨 Check out our latest publication in @JACCJournals #JACCHF! 📄 🫀 Who gets credit when trials span hundreds of sites?🤝 We propose a transparent framework to credit site investigators, coordinators & early-career researchers. #cardiotwitter #research 🔗 doi.org/10.1016/j.jchf.2026.…
1
9
2
31
2,501
Prior to HORIZON we told our patients with elevated Lp(a) that lowering LDL-c to < 55mg/dl and and improving hs-CRP to < 2mg/L ( predominantly by weight loss) that CV risk will be potentially mitigated. HORIZON demonstrates that our recommendations were correct. Attached are figures in the NEJM Supplement that show this very clearly. In the Placebo arm with LDL-C < or > 70 the MACE rate is 10.2 vs 14.8% (45% higher) and CRP < or > 2 is 10.8 vs 16.6% (64% higher). In the subgroups with Lp(a) above or below the median the MACE were basically equivalent. Therefore in the setting of a modestly elevated LDL or CRP the CV risk is markedly elevated in high Lp(a) patients compared to those with low LDL/CRP. Therefore HORIZON teaches us that although lowering Lp(a) with an ASO does not modify the risk we can continue to confidently inform Lp(a) elevated patients of the need to aggressively lower LDL and inflammation (CRP). Much appreciation to Steve Nissen et al and Novartis for a landmark CVOT.
12
40
7
161
37,592
Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels. 1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients. 2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly. 3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering. 4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se. 5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent. 6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason. 7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future. 8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a). I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field. And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies, I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future. With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future. Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.
52
121
18
546
63,063
🚨 #AHA26 #LBCT: ISCHEMIA-EXTEND 🫀 5,179 pts with stable CAD & ≥moderate ischemia (23% women). ⏳Median 9-yr follow-up ⚖️ Invasive vs conservative no difference in: 🔹All-cause death: HR 0.97 (95% CI 0.86–1.09) ❤️ CV death: HR 0.88 (0.75–1.02) 🔹 Non-CV death: HR 1.18 (0.96–1.45) 🎯 GDMT remains foundational. Routine invasive care does NOT improve overall survival. Shared decision-making matters! @JAMA_current #ScientificSessions26 🔗
2
71
4
185
10,651
🎉Prevention takes center stage at #AHA26! 👀My watchlist spans BP, lipids, inflammation & obesity. Beyond the headlines, I’ll be looking for absolute 🫀benefit, safety & sex-specific results. Which trials are you watching? Here is my list (help by AI for the table)! Also why are we using #ScientificSessions26? Such a long hashtag!
4
29
4
133
9,356
Tomorrow morning at #AHA2026 #QCOR 🫯🫀👨🏾‍💻
2
1
8
1,380
Attending #AHA26? Join us for #QCOR Day! 📅 Nov 6 | 8 AM CST 📍S106B #Agentic AI #prevention guidelines #implementation, QCOR debates, fireside chat w @RFRedberg @SharonneHayes , #policy discussions on #access #affordability #Innovation FREE to attend! Hope to see you there! 🙏🏽
9
1
16
968
👏🏾👏🏾👏🏾
🫀 Can coronary atherosclerosis actually regress? Our new randomized FLOWPROMOTE trial analysis, published TODAY in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering! Atherosclerosis is not necessarily a one-way process. 📄 JAMA Cardiology: doi.org/10.1001/jamacardio.2… #Atherosclerosis #LDL #Cardiology #CCTA
145
There is only one thing worse than reading from your slides; That is reading from #AI generated slides #cmgsays And yes, I used AI to generate the image mocking people who use AI. The irony was entirely human-generated. The image is artificial. Unfortunately, the boredom is real. #cmgsays
🤖 Made with AI
17
34
5
221
27,371
🫀Finerenone vs spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. see@ ow.ly/LcYk5100u04 @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava #ESCHeartFailure
3
142
8
413
37,593
I’m so honored to be featured by the Claude team! What a great surprise to get during clinic AngioView.com
Replying to @claudeai
A cardiology fellow built a 3D tool to help trainees learn to read coronary angiograms.
29
148
3
1,601
77,752
I built NavRad Anatomy, a free tool with an AI Guide that makes it simpler to learn clinically important imaging anatomy. To read scans, you need to know the anatomy. But there’s a lot to learn, and it’s hard to know what matters. With this app, you can scroll through real scans with labels and colour-coded overlays, filter the structures you want to see, learn essential anatomy with key clinical pointers, or ask the AI Guide: “Walk me through the liver segments” (see video) “Teach me the segments of the internal carotid artery” Or even: “Just show me the basics” Then test yourself by asking it to quiz you. Works on your phone or computer, so you can learn on the go. See it in action 👇 Try it at anatomy.navigatingradiology.…, or click "Anatomy" in Navigating Radiology.
30
198
6
1,023
65,147
🆕 ACC Scientific Statement on Exercise Prescriptions For CV Health in Adults provides practical, evidence-based guidance to help clinicians confidently prescribe exercise across a wide range of CV conditions. Read the full Scientific Statement ➡️ bit.ly/4hxfedX #JACC
2
97
4
239
11,378
DYSLIPIDEMIA MASTERCLASS: From Lipid Profile to Treatment! High LDL-C? Elevated triglycerides? What about Lp(a)? This 8-part visual guide covers: ⭕Lipoproteins & lipid interpretation ⭕ Cardiovascular risk assessment ⭕ Primary & secondary dyslipidemias ⭕ Statins & non-statin therapies ⭕ Hypertriglyceridemia & pancreatitis prevention ⭕ Lp(a), HDL-C & special populations ⭕ Guideline-based treatment algorithms Updated with the 2026 ACC/AHA Dyslipidemia Guideline and 2025 ESC/EAS Focused Update. Learn it. Apply it. Save it.
3
220
3
791
38,350
The same receptor does not mean the same evidence. At HFSA 2026 in Phoenix, I discussed steroidal versus nonsteroidal mineralocorticoid receptor antagonists (MRAs), and why choosing the right agent matters, particularly in HFmrEF/HFpEF. Steroidal MRAs remain foundational in HFrEF. Spironolactone and eplerenone have established benefits for survival and HF hospitalization. The question is how far we should extrapolate their evidence across the ejection fraction spectrum. In HFmrEF/HFpEF, the evidence differs by agent. TOPCAT did not meet its primary endpoint with spironolactone, although HF hospitalizations were reduced. That is not “no benefit,” but neither is it an unequivocally positive outcomes trial. FINEARTS-HF demonstrated a 16% reduction in the composite rate of total worsening HF events and cardiovascular death with finerenone in patients with LVEF ≥40%. That distinction informed my challenge to the 2026 ESC guidelines’ Class I recommendation encompassing both steroidal and nonsteroidal MRAs in HFpEF: does a broad recommendation adequately communicate the differences in the supporting evidence? Guideline simplicity should not obscure those differences. Safety deserves the same precision. Early head-to-head data suggest potential potassium and kidney tolerability advantages for finerenone over spironolactone in selected patients; but they do not establish superior long-term HF outcomes. And nonsteroidal does not mean risk-free: finerenone also increases hyperkalemia risk and monitoring is warranted. My take-home message: we should neither assume interchangeability nor claim superiority from separate placebo-controlled trials. We should choose the agent supported by the strongest evidence for the patient’s HF phenotype, while accounting for comorbidities, tolerability, and access.
5
10
44
3,692
👉Lp(a)HORIZON: could tolerability and treatment exposure have influenced the result? 👆Targeted Lp(a)-lowering therapies: tolerability matters too. 1⃣ Emerging therapies achieve substantial Lp(a) reductions, with generally favorable safety profiles in early trials. 2⃣ In pelacarsen’s phase 2 trial, injection-site reactions occurred in 27% vs 6% with placebo, while discontinuation due to adverse events was similar: 5% vs 4%. 3⃣ More local reactions do not necessarily translate into treatment withdrawal or reduced exposure. 4⃣ Comparisons across agents require caution: dosing schedules, follow-up and adverse-event reporting differ between trials. 5⃣ Adherence and sustained Lp(a) lowering may help contextualize cardiovascular outcome findings, including HORIZON. Any contribution of treatment interruptions to its negative result remains speculative. Substantial Lp(a) lowering is established. Its translation into cardiovascular benefit remains the key question. The depth and duration of Lp(a) lowering may matter. Whether reduced treatment exposure contributed to HORIZON’s result remains an open question. 🔗doi.org/10.1016/j.jacl.2026.… @society_eas @LipidJournal @nationallipid
4
13
2
38
4,037